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Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Dominican Republic, in 
patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have 
failed to chemotherapy with Docetaxel. MethOds: A three-health state cohort sim-
ulation Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Dominican Republic. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years 
(LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC 
for C-P). Utilities for health states and negative utilities for adverse events were 
estimated based on quality of life endpoints of the COU-AA-301 trial. The base year 
was 2012. All costs are presented in Dominican currency (Dominican Pesos - RD$). 
Costs and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis 
was performed to evaluate uncertainty surrounding the parameters. Results: 
A-P resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: RD$ 
2.204.289 for A-P and RD$ 2.732.365 for C-P. The results of the probabilistic sensitivity 
analysis showed that, when compared with C-Z, A-P was found dominant (associ-
ated with reduced costs and increased QALYs) in the majority of the iterations. A-P 
had a 75% probability of being cost effective, independent of the willingness to pay, 
when compared to C-P. cOnclusiOns: A-P can be considered cost-saving (domi-
nant), when compared with C-P, in patients with Metastatic Castration-Resistant 
Prostate Cancer that have failed to chemotherapy with Docetaxel, from the perspec-
tive of the Public System of Health of Dominican Republic.
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Objectives: Modern therapeutic approaches in treatment of advanced breast 
cancer can achieve clinically significant regression of symptoms, prolong life and 
improve its quality. Aim of this study was to conduct clinical and economic analysis 
of application of everolimus in the treatment of hormone-receptor-positive (HR+), 
human epidermal growth factor receptor-2-negative (HER2-) advanced breast can-
cer in postmenopausal women. MethOds: An epidemiological and pharmaco-
economic evaluation of HR+, HER2- advanced breast cancer in postmenopausal 
women with using a survey of experts from different regions of Russia and mod-
eling method. Calculating the cost of drugs and medical services was conducted 
according to experts and standard of medical care. Filling of a Markov model was 
conducted without using and with using of everolimus in the treatment of the 
patients within 5 years. Calculated indicators were: the impact of the disease on 
budget, the cost of one additional year of life. Results: From 13 regions of Russia 
8 experts refused to provide information on the questionnaire, which may indicate 
the unwillingness to disclose information on epidemiology and tactics of treatment 
of disease. The burden of breast cancer for 5 years without the use of everolimus 
in the treatment regimens of patients with postmenopausal HR+, HER2- advanced 
breast cancer and with using it were: in Moscow 118.668.419€ and 137.596.651€ ; 
St. Petersburg-36.730.318€ and 38.133.492€ ; Republic of Khakassia-18.854.270€ and 
19.812.467€ ; Omsk region-32.428.540€ and 33.603.456€ ; Primorsky Krai-39.176.077€ 
and 40.877.880€ . The use of of everolimus with exemestane in the treatment of 
advanced breast cancer increases by 1.5-2 times life expectancy and its “cost-effec-
tiveness” indicator is 2 times lower comparing to exemestane monotherapy and 
chemotherapy. Sensitivity analysis using the results from 5 regions of Russia showed 
unidirectional comparison. cOnclusiOns: The use of everolimus with exemestane 
is the dominant technology of treatment HR+, HER2- advanced breast cancer in 
postmenopausal patients compared with traditional technology of application of 
chemotherapy drugs or exemestane alone.
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Objectives: Lung cancers are the most common malignant tumours, account-
ing for 1.38 million annual deaths worldwide. Non-small cell lung cancer (NSCLC), 
the predominant tumour subtype, is associated with significant deteriorations in 
both survival and quality of life. Epidermal growth factor receptor tyrosine kinase 
(EGFR-TK) has emerged as a drug therapy target. The National Institute for Health 
and Care Excellence (NICE) recommends erlotinib – an EGFR-TK inhibitor – for 
first-line treatment of NSCLC in EGFR-TK mutation-positive patients, and second-
line treatment in all patients irrespective of EGFR-TK mutations. We developed 
a model to assess the cost-effectiveness of an EGFR-TK mutation status-guided 
treatment strategy for stage III/IV NSCLC, compared with a strategy not depend-
ent on mutational status. MethOds: A Markov model was developed from the 
perspective of the UK National Health Service (NHS) over a lifetime horizon. This 
compared a current scenario (in which a cohort of NSCLC patients received dou-
blet chemotherapy at first-line therapy, followed either by erlotinib or docetaxel at 
second-line) to a revised scenario (in which all EGFR-TK mutation-positive patients 
received erlotinib at first-line followed by second-line docetaxel, and all mutation-
negative patients received doublet chemotherapy followed by either docetaxel or 
Markov model was developed to estimate the health outcome (QALY) and total 
treatment costs with Markov cycle of 21 days and lifetime horizon. The effec-
tiveness data was retrieved from the randomized clinical trial ECOG 4599. Direct 
costs, including cost of drugs, administration, medical services, hospital bed day 
and adverse drug reaction management were estimated based on treatment 
guideline of NCCN for NSCLC. Indirect costs, including loss of earnings, cost for 
meal, transportation, accomodation of patients and their caregivers due to treat-
ment, were estimated based on survey of a cohort of 87 patients with NSCLC 
in HCMC Oncology Hospital. Both cost and effectiveness were discounted 3% 
annually. Results: Adding bevacizumab to PC regimen in first-line therapy of 
advanced NSCLC patients resulted in incremental QALY gained of 2.26 month 
compared with PC regimen (7.88 versus 5.62). The total treatment cost with BCP 
was 3 times higher than PC (2,499 millions vs 761.7 millions VND, respectively). 
ICER of BCP versus PC was 768,732,924 VND, which is 3.35 times higher than the 
Willingness-To-Pay of Vietnam in 2013 (229,242,416 VND). A probability sensitivity 
analysis demonstrated the patient’s weight and bevacizumab’s price as the most 
affecting factors to the ICER of BCP vs PC. cOnclusiOns: Conducted analysis 
showed that combination of bevacizumab and PC regimen in first-line therapy 
of NSCLC was not cost-effective compared with PC regimen. Support from the 
manufactures, suppliers and insurance organizations are neccessary to raise its 
economic effectiveness in treatment of advanced NSCLC.
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Objectives: Colorectal cancer (CRC) screening using computerised tomographic 
colonography (CTC), also referred to as virtual colonography, has attracted consider-
able attention due to its positive impact on high screening uptake rates, especially 
with a laxative-free preparation before screening. A decision analysis model was 
constructed in order to evaluate the clinical and economic consequences of per-
forming three different screening tests versus a no screening scenario in a popula-
tion at average risk of colorectal cancer in Germany: colonoscopy, conventional 
CT-colonography and laxative-free CT colonography. MethOds: A state-transition 
microsimulation was developed for the evaluation of the different screening strate-
gies using TreeAge Pro Healthcare 2014. A hypothetic population of 100,000 German 
asymptomatic adults aged between 50 and 100 years was used for the basis of the 
model. The simulation of the screening strategies was undertaken by assessing the 
number of screening patients diagnosed with CRC on the basis of the sensitivity 
and specificity of each strategy and the related uptake of each screening method. 
Sensitivity analysis will be applied to test the impact of parameter uncertainty on 
model outcomes and recommendations. Results: Initial results of the simula-
tion show that laxative-free colonography was found to be the most costly screen-
ing option, with a total cost of EUR 4,115 per screening patient in the simulation 
model. Colonoscopy was found to be the least costly screening method, with total 
equivalent costs of EUR 2,132. The most effective screening was modeled for laxa-
tive-free colonography. The ICER of laxative-free colonography compared to colonos-
copy was simulated at 5,221 EUR per life year saved. cOnclusiOns: Our simulation 
has shown that using data from new research indicating the possibility of less costly 
use of CTC than previously used for modeling, laxative-free CTC screening has the 
potential to become a cost-effective alternative screening method for CRC due to 
its advantage related to improvements in screening uptake.
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Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Costa Rica, in patients 
with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have failed to 
chemotherapy with Docetaxel. MethOds: A three-health state cohort simula-
tion Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Costa Rica. The health 
outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years (LYs). 
Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC for C-P). 
Utilities for health states and negative utilities for adverse events were estimated 
based on quality of life endpoints of the COU-AA-301 trial. The base year was 2012. 
All costs are presented in Costa Rican currency (Colones - CRC). Costs and outcomes 
were discounted at 5%. Probabilistic sensitivity (PSA) analysis was performed to 
evaluate uncertainty surrounding the parameters. Results: A-P resulted in 0.79 
QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 QALYs and 1.28 
LYs, per patient, respectively. Mean total costs per patient were: CRC 33.881.184 for 
A-P and CRC 41.981.207 for C-P. The results of the probabilistic sensitivity analysis 
showed that, when compared with C-Z, A-P was found dominant (associated with 
reduced costs and increased QALYs) in the majority of the iterations. A-P had an 
89% probability of being cost effective, independent of the willingness to pay, when 
compared to C-P. cOnclusiOns: A-P can be considered dominant (cost-saving), 
when compared with C-P, in patients with Metastatic Castration-Resistant Prostate 
Cancer that have failed to chemotherapy with Docetaxel, from the perspective of 
the Public System of Health of Costa Rica.
